Company Directory - Research & Development
We research, develop and commercialize high quality, affordable, ready-to-formulate ingredients that are based on nature and are available at all times, in any quantity. We believe in applying technology platforms, such as fermentation, to help resolve sourcing bottlenecks in nature.
F2G is a world-leading UK- and Austria-based Biotech company (F2G Ltd and F2G Biotech GmbH) focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides.
Fog City Bio is a Bay Area micro-CRO specializing in rapid ELISA and immunoassay optimization for biotech R&D teams. We rescue underperforming assays and develop fit-for-purpose protein assays (e.g., ELISA, kinetics, HTRF, TR-FRET, etc.)
Genialis is a computational precision medicines company unravelling complex biology to find new ways to address disease. ResponderID™, Genialis’ clinical biomarker discovery platform, defines, models, and validates actionable biomarkers and optimally positions novel drugs to accelerate translational research and clinical development.
Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
We deliver the understanding of the genomic drivers of every disease for Pharma. Our curated Genomic Landscapes provide immediate insight into the genomic evidence for every phenotype, disease, gene, and variant.
We’re committed to creating possible. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.
GlycoMimetics is a hematology-oncology focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.
